Amneal Pharmaceuticals, Inc.
AMRX
Jodie situation report
Amneal Pharmaceuticals, Inc.'s move is spreading beyond its market group.
AMRX accounts for 5.4% of the group's measured movement across 3.9 effective names. raw member direction is mixed; 6 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 28%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
No material onset for AMRX could be timestamped inside the aligned 5-minute window.
- Revenue increased 9.9% versus the comparable filing period.
6 of 24 members in Airline Operators are active. 0 of 8 disclosed connections are confirming.
- At least 16 of 24 durable members become active together.
- Capital-flow agreement rises above 55%.
- DRI remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 8 of 24 members or fewer.
Who this business touches
The relationships behind AMRX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
SPRYARS Pharmaceuticals, Inc.competitorMay 15, 2026 ▾
“Additionally, the development of new treatment methods for the diseases we are targeting could render our current or future product candidates non-competitive or obsolete.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 14 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
AMRX is currently a Participant in the organic co-movement group Airline Operators. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.